PMID- 31428232 OWN - NLM STAT- MEDLINE DCOM- 20200103 LR - 20231013 IS - 1942-0994 (Electronic) IS - 1942-0900 (Print) IS - 1942-0994 (Linking) VI - 2019 DP - 2019 TI - An Update on Novel Therapeutic Warfronts of Extracellular Vesicles (EVs) in Cancer Treatment: Where We Are Standing Right Now and Where to Go in the Future. PG - 9702562 LID - 10.1155/2019/9702562 [doi] LID - 9702562 AB - Extracellular vesicles (EVs) are a heterogeneous group of membrane-bounded vesicles that are believed to be produced and secreted by presumably all cell types under physiological and pathological conditions, including tumors. EVs are very important vehicles in intercellular communications for both shorter and longer distances and are able to deliver a wide range of cargos including proteins, lipids, and various species of nucleic acids effectively. EVs have been emerging as a novel biotherapeutic platform to efficiently deliver therapeutic cargos to treat a broad range of diseases including cancer. This vast potential of drug delivery lies in their abilities to carry a variety of cargos and their ease in crossing the biological membranes. Similarly, their presence in a variety of body fluids makes them a potential biomarker for early diagnosis, prognostication, and surveillance of cancer. Here, we discuss the relatively least and understudied aspects of EV biology and tried to highlight the obstacles and limitations in their clinical applications and also described most of the new warfronts to beat cancer at multiple stages. However, much more challenges still remain to evaluate EV-based therapeutics, and we are very much hopeful that the current work prompts further discovery. FAU - Khawar, Muhammad Babar AU - Khawar MB AUID- ORCID: 0000-0002-1812-0591 AD - State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China. AD - University of Chinese Academy of Sciences, Beijing 100049, China. AD - Cell & Molecular Biology Lab, Department of Zoology, University of the Punjab, Lahore, Pakistan. FAU - Abbasi, Muddasir Hassan AU - Abbasi MH AUID- ORCID: 0000-0001-7856-7013 AD - Cell & Molecular Biology Lab, Department of Zoology, University of the Punjab, Lahore, Pakistan. AD - Department of Zoology, University of Okara, Okara, Pakistan. FAU - Siddique, Zerwa AU - Siddique Z AD - Centre for Applied Molecular Biology (CAMB), University of the Punjab, Lahore, Pakistan. FAU - Arif, Amin AU - Arif A AD - Cell & Molecular Biology Lab, Department of Zoology, University of the Punjab, Lahore, Pakistan. FAU - Sheikh, Nadeem AU - Sheikh N AUID- ORCID: 0000-0001-9503-9538 AD - Cell & Molecular Biology Lab, Department of Zoology, University of the Punjab, Lahore, Pakistan. LA - eng PT - Journal Article PT - Review DEP - 20190725 PL - United States TA - Oxid Med Cell Longev JT - Oxidative medicine and cellular longevity JID - 101479826 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers) RN - 0 (Cancer Vaccines) RN - 0 (Drug Carriers) RN - 0 (MicroRNAs) SB - IM MH - Animals MH - Antineoplastic Agents/chemistry/therapeutic use MH - Biomarkers/metabolism MH - Cancer Vaccines/immunology MH - Dendritic Cells/immunology/metabolism MH - Drug Carriers/chemistry MH - Extracellular Vesicles/chemistry/immunology/*metabolism MH - Humans MH - MicroRNAs/metabolism MH - Neoplasms/diagnosis/*drug therapy/immunology PMC - PMC6683766 COIS- The authors declare no conflict of interests. EDAT- 2019/08/21 06:00 MHDA- 2020/01/04 06:00 PMCR- 2019/07/25 CRDT- 2019/08/21 06:00 PHST- 2019/03/18 00:00 [received] PHST- 2019/06/03 00:00 [revised] PHST- 2019/07/04 00:00 [accepted] PHST- 2019/08/21 06:00 [entrez] PHST- 2019/08/21 06:00 [pubmed] PHST- 2020/01/04 06:00 [medline] PHST- 2019/07/25 00:00 [pmc-release] AID - 10.1155/2019/9702562 [doi] PST - epublish SO - Oxid Med Cell Longev. 2019 Jul 25;2019:9702562. doi: 10.1155/2019/9702562. eCollection 2019.